Multifaceted regenerative lives of expired platelets in the second decade of the 21st century

Transfusion and Apheresis Science

Volumn 51, Issue 2, 2014, Pages 107-112

  Burnouf, Thierry ^a   Goubran, Hadi Alphonse ^b   Seghatchian, Jerard ^c  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c International Consultancy in Blood Components Quality Safety Improvement   (United Kingdom)

Author keywords

Ex vivo cell expansion; Expired platelets; Hemostatic wound healing products; Infusible platelet membrane; Platelet lysates microparticles growth factors; Regenerative medicine cell therapy

Indexed keywords

THROMBOCYTE CONCENTRATE; HEMOSTATIC AGENT; SIGNAL PEPTIDE;

BLOOD TRANSFUSION; CELL EXPANSION; CELL LYSATE; EX VIVO STUDY; EXPIRATION DATE; HUMAN; PLATELET MICROPARTICLE; REGENERATIVE MEDICINE; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE MEMBRANE; THROMBOCYTE TRANSFUSION; BLOOD STORAGE; CELL MEMBRANE; CHEMISTRY; PROCEDURES; THROMBOCYTE;

BLOOD PLATELETS; BLOOD PRESERVATION; CELL MEMBRANE; HEMOSTATICS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; REGENERATIVE MEDICINE;

EID: 84922616163     PISSN: 14730502     EISSN: 18781683     Source Type: Journal    
DOI: 10.1016/j.transci.2014.08.006     Document Type: Review

References (52)

1. Davi G., Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007, 357:2482-2494.
2. Verma A., Agarwal P. Platelet utilization in the developing world: strategies to optimize platelet transfusion practices. Transfus Apher Sci 2009, 41:145-149.
3. Radosevich M., Goubran H.A., Burnouf T. Fibrin sealant: scientific rationale, production methods, properties, and current clinical use. Vox Sang 1997, 72:133-143.
4. Spotnitz W.D. Fibrin sealant in the United States: clinical use at the University of Virginia. Thromb Haemost 1995, 74:482-485.
5. Marx R.E. Platelet-rich plasma: evidence to support its use. J Oral Maxillofac Surg 2004, 62:489-496.
6. Marx R.E., Carlson E.R., Eichstaedt R.M., Schimmele S.R., Strauss J.E., Georgeff K.R. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998, 85:638-646.
7. Burnouf T., Goubran H.A., Chen T.M., Ou K.L., El-Ekiaby M., Radosevic M. Blood-derived biomaterials and platelet growth factors in regenerative medicine. Blood Rev 2013, 27:77-89.
8. Filardo G., Kon E., Pereira Ruiz M.T., Vaccaro F., Guitaldi R., Di Martino A., et al. Platelet-rich plasma intra-articular injections for cartilage degeneration and osteoarthritis: single- versus double-spinning approach. Knee Surg Sports Traumatol Arthrosc 2012, 20:2082-2091.
9. Andia I., Sanchez M., Maffulli N. Joint pathology and platelet-rich plasma therapies. Expert Opin Biol Ther 2012, 12:7-22.
10. Weiner B.K., Walker M. Efficacy of autologous growth factors in lumbar intertransverse fusions. Spine (Phila Pa 1976) 2003, 28:1968-1970. discussion 1971.
11. Sampson S., Reed M., Silvers H., Meng M., Mandelbaum B. Injection of platelet-rich plasma in patients with primary and secondary knee osteoarthritis: a pilot study. Am J Phys Med Rehabil 2010, 89:961-969.
12. Sanchez M., Guadilla J., Fiz N., Andia I. Ultrasound-guided platelet-rich plasma injections for the treatment of osteoarthritis of the hip. Rheumatology (Oxford) 2012, 51:144-150.
13. van Buul G.M., Koevoet W.L., Kops N., Bos P.K., Verhaar J.A., Weinans H., et al. Platelet-rich plasma releasate inhibits inflammatory processes in osteoarthritic chondrocytes. Am J Sports Med 2011, 39:2362-2370.
14. Nurden A.T., Nurden P., Sanchez M., Andia I., Anitua E. Platelets and wound healing. Front Biosci 2008, 13:3532-3548.
15. Di Michele M., Van Geet C., Freson K. Recent advances in platelet proteomics. Expert Rev Proteomics 2012, 9:451-466.
16. Blair P., Flaumenhaft R. Platelet alpha-granules: basic biology and clinical correlates. Blood Rev 2009, 23:177-189.
17. Snyder E.L., Calhoun B.C. Topical platelet growth factor therapy: of lotions and potions. Transfusion 2001, 41:1186-1189.
18. Chen T.M., Tsai J.C., Burnouf T. A novel technique combining platelet gel, skin graft, and fibrin glue for healing recalcitrant lower extremity ulcers. Dermatol Surg 2010, 36:453-460.
19. Chen T.M., Tzeng Y.S., Tsai J.C., Burnouf T. Single-donor allogeneic platelet fibrin glue and osteoconductive scaffold in orbital floor fracture reconstruction. Ann Plast Surg 2013, 70:370-374.
20. Greppi N., Mazzucco L., Galetti G., Bona F., Petrillo E., Smacchia C., et al. Treatment of recalcitrant ulcers with allogeneic platelet gel from pooled platelets in aged hypomobile patients. Biologicals 2011, 39:73-80.
21. Hervig T., Seghatchian J., Apelseth T.O. Current debate on pathogen inactivation of platelet concentrates - to use or not to use?. Transfus Apher Sci 2010, 43:411-414.
22. Seghatchian J., Hervig T., Putter J.S. Effect of pathogen inactivation on the storage lesion in red cells and platelet concentrates. Transfus Apher Sci 2011, 45:75-84.
23. Chan R.K., Liu P., Lew D.H., Ibrahim S.I., Srey R., Valeri C.R., et al. Expired liquid preserved platelet releasates retain proliferative activity. J Surg Res 2005, 126:55-58.
24. WHO. WHO guidelines on tissue infectivity distribution in transmissible spongiform encephalopathies. 2010. <>. http://www.who.int/bloodproducts2006.
25. CHMP Note for guidance on the use of bovine serum in the manufacture of human biological medicinal products 2003, European Medicine Agency, London, CPMP/BWP/1793/02. http://www.emea.eu.int.
26. Spees J.L., Gregory C.A., Singh H., Tucker H.A., Peister A., Lynch P.J., et al. Internalized antigens must be removed to prepare hypoimmunogenic mesenchymal stem cells for cell and gene therapy. Mol Ther 2004, 9:747-756.
27. Heiskanen A., Satomaa T., Tiitinen S., Laitinen A., Mannelin S., Impola U., et al. N-glycolylneuraminic acid xenoantigen contamination of human embryonic and mesenchymal stem cells is substantially reversible. Stem Cells 2007, 25:197-202.
28. Robertson J.S. Bovine serum - regulatory issues. Dev Biol (Basel) 2006, 123:269-272. discussion 291-308.
29. Hill A.F., Desbruslais M., Joiner S., Sidle K.C.L., Gowland I., Collinge J., et al. The same prion strain causes vCJD and BSE. Nature 1997, 389:448-450.
30. van der Valk J., Mellor D., Brands R., Fischer R., Gruber F., Gstraunthaler G., et al. The humane collection of fetal bovine serum and possibilities for serum-free cell and tissue culture. Toxicol in Vitro 2004, 18:1-12.
31. Gstraunthaler G. Alternatives to the use of fetal bovine serum: serum-free cell culture. ALTEX 2003, 20:275-281.
32. Doucet C., Ernou I., Zhang Y., Llense J.R., Begot L., Holy X., et al. Platelet lysates promote mesenchymal stem cell expansion: a safety substitute for animal serum in cell-based therapy applications. J Cell Physiol 2005, 205:228-236.
33. Bieback K., Hecker A., Kocaomer A., Lannert H., Schallmoser K., Strunk D., et al. Human alternatives to fetal bovine serum for the expansion of mesenchymal stromal cells from bone marrow. Stem Cells 2009, 27:2331-2341.
34. Schallmoser K., Bartmann C., Rohde E., Reinisch A., Kashofer K., Stadelmeyer E., et al. Human platelet lysate can replace fetal bovine serum for clinical-scale expansion of functional mesenchymal stromal cells. Transfusion 2007, 47:1436-1446.
35. Jonsdottir-Buch S.M., Lieder R., Sigurjonsson O.E. Platelet lysates produced from expired platelet concentrates support growth and osteogenic differentiation of mesenchymal stem cells. PLoS ONE 2013, 8:e68984.
36. Fekete N., Gadelorge M., Furst D., Maurer C., Dausend J., Fleury-Cappellesso S., et al. Platelet lysate from whole blood-derived pooled platelet concentrates and apheresis-derived platelet concentrates for the isolation and expansion of human bone marrow mesenchymal stromal cells: production process, content and identification of active components. Cytotherapy 2012, 14:540-554.
37. Kocaoemer A., Kern S., Kluter H., Bieback K. Human AB serum and thrombin-activated platelet-rich plasma are suitable alternatives to fetal calf serum for the expansion of mesenchymal stem cells from adipose tissue. Stem Cells 2007, 25:1270-1278.
38. Iudicone P., Fioravanti D., Bonanno G., Miceli M., Lavorino C., Totta P., et al. Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells. J Transl Med 2014, 12:28.
39. Stahle M.U., Brandhorst D., Korsgren O., Knutson F. Pathogen inactivation of human serum facilitates its clinical use for islet cell culture and subsequent transplantation. Cell Transplant 2011, 20:775-781.
40. Stahle M., Carlsson B., Le Blanc K., Korsgren O., Knutson F. Photochemical pathogen inactivation of human serum enables its large-scale application in clinical cell transplantation. Vox Sang 2010, 98:e364-e365.
41. Burnouf T., Tseng Y.H., Kuo Y.P., Su C.Y. Solvent/detergent treatment of platelet concentrates enhances the release of growth factors. Transfusion 2008, 48:1090-1098.
42. Su C.Y., Kuo Y.P., Lin Y.C., Huang C.T., Tseng Y.H., Burnouf T. A virally inactivated functional growth factor preparation from human platelet concentrates. Vox Sang 2009, 97:119-128.
43. Shih D.T., Chen J.C., Chen W.Y., Kuo Y.P., Su C.Y., Burnouf T. Expansion of adipose tissue mesenchymal stromal progenitors in serum-free medium supplemented with virally inactivated allogeneic human platelet lysate. Transfusion 2011, 51:770-778.
44. Burnouf T., Chang C.W., Kuo Y.P., Wu Y.W., Tseng Y.H., Su C.Y. A chromatographically purified human TGF-beta1 fraction from virally inactivated platelet lysates. Vox Sang 2011, 101:215-220.
45. Burnouf T., Kuo Y.P., Huang C.T., Tseng Y.H., Lin C.T., Su C.Y. A virally inactivated platelet-derived growth factor/vascular endothelial growth factor concentrate fractionated from human platelets. Transfusion 2010, 50:1702-1711.
46. Burnouf T., Kuo Y.P., Blum D., Burnouf S., Su C.Y. Human platelet concentrates: a source of solvent/detergent-treated highly enriched brain-derived neurotrophic factor. Transfusion 2012, 52:1721-1728. 10.1111/j.1537-2995.2011.03494.x.
47. Wolf P. The nature and significance of platelet products in human plasma. Br J Haematol 1967, 13:269-288.
48. Warren B.A., Vales O. The release of vesicles from platelets following adhesion to vessel walls in vitro. Br J Exp Pathol 1972, 53:206-215.
49. Sinauridze E.I., Kireev D.A., Popenko N.Y., Pichugin A.V., Panteleev M.A., Krymskaya O.V., et al. Platelet microparticle membranes have 50-to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost 2007, 97:425-434.
50. Nasiri S. Infusible platelet membrane as a platelet substitute for transfusion: an overview. Blood Transfus 2013, 11:337-342.
51. Fitzpatrick G.M., Cliff R., Tandon N. Thrombosomes: a platelet-derived hemostatic agent for control of noncompressible hemorrhage. Transfusion 2013, 53(Suppl. 1):100S-106S.
52. Tseng Y, Liu K, Ku C, Burnouf T. Standardized human platelet lysate supplement demonstrates to be an effective, serum-free, xeno-free, FBS replacement for culturing AT-/BM-/and UC-mesenchymal stem cells. Cytotherapy 2014, 16:S85.